Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-10-02
2011-10-25
Angell, J. E. (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
Reexamination Certificate
active
08044032
ABSTRACT:
Novel methods and compositions for selective killing of cells by activation of PKR are disclosed. In a preferred embodiment, a method is provided for causing cell death in a targeted population of cells that includes the steps of: selecting a nucleotide sequence at a single genetic locus in the targeted population that is absent from the equivalent locus in a population of non-targeted cells; obtaining one or more anti-sense RNA having sequence homology with the locus in the targeted population; permitting the anti-sense RNA to hybridize with an RNA transcribed from the locus in the targeted population so as to form a contiguous double stranded RNA for interacting with PKR. The activation of PKR gives rise to selective cell death in the targeted population.
REFERENCES:
patent: 5624803 (1997-04-01), Noonberg et al.
patent: 5734039 (1998-03-01), Calabretta et al.
patent: 5955306 (1999-09-01), Gimeno et al.
patent: 5994314 (1999-11-01), Eljamal et al.
patent: 5997858 (1999-12-01), Tovey et al.
patent: 6150110 (2000-11-01), Fletcher et al.
patent: 2003/0153083 (2003-08-01), Shir et al.
patent: WO 92/22303 (1992-12-01), None
patent: WO 96/18733 (1996-06-01), None
patent: WO 97/17456 (1997-05-01), None
patent: WO 98/54315 (1998-12-01), None
patent: WO 01/57205 (2001-09-01), None
Agrawal et al. “Antisense Therapeutics: Is It as Simple as Complementary Base Recognition?”, Molecular Medicine Today: Reviews, 61: 72-81, 2000.
Opalinska et al. “Nucleic-Acid Therapeutics: Basic Principles and Recent Applications”, Nature Reviews: Drug Discovery, 1: 503-514, 2002.
Jen et al. “Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies”, Stem Cells, 18: 307-319, 2000.
Crooke “Progress in Antisense Technology”, Annual Reviews in Medicine, 55: 61-95, 2004.
Deglon et al, “Self-Inactivating Lentiviral Vectors with Enhanced Transgene Expression as Potential Gene Transfer System in Parkinson's Disease”,Human Gene Therapy, 11:179-190, 2000.
Manche et al, “Interactions Between Double-Stranded RNA Regulators and the Protein Kinase DAI”,Molecular and Cellular Biology, 12(11):5238-5248, 1992.
Jagus et al, “PKR, Apoptosis and Cancer”,Int'l J. of Biochem and Cell Biol., 31:123-138, 1999.
Yukai et al, “Inhibition of Human Squamous Cell Carcinoma Growth In Vivi by Epidermal Growth factor Receptor Antisense RNA Transcribed From the bU6 Promoter”,J. Nat'l Cancer Inst., 90(14):1080-1087, 1998.
Ben-Asouli et al, “Human Interferon-Gamma mRNA Regulates its own Translation Through local Activation of the Protein Kinase PKR”,J. Interferon and Cytokine Research, 19(Supp 1):S101, 1999.
Asubel et al,Eds., A Compendium of Methods from Current Protocols in Molecular Biology,John Wiley&Sons, Inc., Chap. 6, 1992.
Balachandran et al, “Activation of the dsRNA-dependent protein kinase, PKR, induces apoptosis through FADD-mediated death signaling”,EMBO J.Dec. 1, 1998;17(23):6888-902.
Davies et al, “The vaccinia virus K3L gene product potentiates translation by inhibiting double-stranded-RNA-activated protein kinase and phosphorylation of the alpha subunit of eukaryotic initiation factor 2”,J Virol.Apr. 1992;66(4):1943-50.
Cleary et al, “Cloning and structural analysis of cDNAs for bc1-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation”,Cell.Oct. 10, 1986;47(1):19-28.
Clemens, MJ, “Regulation of eukaryotic protein synthesis by protein kinases that phosphorylate initiation factor eIF-2”,Mol Biol Rep.May 1994;19(3):201-10.
Clemens et al, “Inhibition of protein synthesis in rabbit reticulocyte lysates by double-stranded RNA and oxidized glutathione: indirect mode of action on polypeptide chain initiation”,Proc Natl Acad Sci U S A. Apr. 1975;72(4):1286-90.
Corry, S., “Activation of cellular oncogenes in hemopoietic cells by chromosome translocation”,Adv Cancer Res.1986;47:189-234.
Davies et al, “The E3L and K3L vaccinia virus gene products stimulate translation through inhibition of the double-stranded RNA-dependent protein kinase by different mechanisms”,J Virol.Mar. 1993;67(3):1688-92.
Zufferey et al, “Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo”,Nat Biotechnol.Sep. 1997;15(9):871-5.
Donze et al, “Abrogation of translation initiation factor eIF-2 phosphorylation causes malignant transformation of NIH 3T3 cells”,EMBO J.Aug. 1, 1995;14(15):3828-34.
Edwards et al, “A simple and rapid method for the preparation of plant genomic DNA for PCR analysis”,Nucleic Acids Res.Mar. 25, 1991;19(6):1349.
Farrell et al, “Phosphorylation of initiation factor eIF-2 and the control of reticulocyte protein synthesis”,Cell.May 1977;11(1):187-200.
Fischer et al, “A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene”,Blood. Jul. 1988;72(1):234-40.
He et al, “Growth Inhibition of Human Papillomavirus 16 DNA-Positive Mouse Tumor by Antisense RNA Transcribed form U6 Promoter”,Cancer Research, 57:3993-9, 1997.
He et al, “Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter”,J Natl Cancer Inst. Jul. 15, 1998;90(14):1080-7. Erratum in:J Natl Cancer InstApr. 17, 2002;94(8):633.
Hunter et al, “The characteristics of inhibition of protein synthesis by double-stranded ribonucleic acid in reticulocyte lysates”,J Biol Chem.Jan. 25, 1975;250(2):409-17.
Hurwitz et al, “Characterization of a leukemic cell line of the pre-B phenotype”,Int J Cancer. Feb. 1979;23(2):174-80.
Jagus et al, “PKR, Apopstosis and Cancer”,Int. J. Biochem.&Cell Biol., 31:123-138, 1999.
Jereb et al, “Addition of IFN-alpha to treatment of malignant brain tumors”,Acta Oncol.1994;33(6):651-4.
Koromilas et al, “Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent protein kinase”,Science. Sep. 18, 1992;257(5077):1685-9.
Kunkel et al, “Transcription of a human U6 small nuclear RNA gene in vivo withstands deletion of intragenic sequences but not of an upstream TATATA box.”,Nucleic Acids. Res. Sep. 25, 1989;17(18):7371-9.
Lee et al, “The interferon-induced double-stranded RNA-activated protein kinase induces apoptosis”,Virology. Mar. 1994;199(2):491-6.
Levin et al, “Characterization of double-stranded-RNA-activated kinase that phosphorylates alpha subunit of eukaryotic initiation factor 2 (eIF-2 alpha) in reticulocyte lysates”,Proc Natl Acad Sci U S A. Feb. 1980;77(2):832-6.
Levin et al, “Regulation of Protein Synthesis: Activation by double-stranded RNA of a Protein Kinase that Phosphorylates initiation factor 2”,Proc Natl Acad Sci U S A., 75(3):1121-1125, 1978.
Morris et al, “Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma”,Science. Jan. 20, 1995;267(5196):316-7.
Naldini et al, “In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector”,Science. Apr. 12, 1996;272(5259):263-7.
Nishikawa et al, “A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity”,Proc Natl Acad Sci U S A. Aug. 2, 1994;91(16):7727-31.
Ong et al, “Chromosomal Abnormalities and Molecular Genetics of Non-Hidgkins Lymphoma”,Seminars in Oncology, 25(4) 447-460, 1998.
Pain, VM, “Initiation of protein synthesis in eukaryotic cells”,Eur J Biochem. Mar. 15, 1996;236(3):747-71.
Patel et al, “PACT, a protein activator of the interferon-induced protein kinase, PKR”,EMBO J. Aug. 3, 1998;17(15):4379-90.
Sood et al, “A mammalia
Levitzki Alexander
Shir Alexei
Angell J. E.
Yissum Research Development Company of the Hebrew University of
LandOfFree
Selective killing of cells by activation of double-stranded... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Selective killing of cells by activation of double-stranded..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selective killing of cells by activation of double-stranded... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4289475